Immune mechanisms in malaria: New insights in vaccine development

Nature Medicine

Volumn 19, Issue 2, 2013, Pages 168-178

  Riley, Eleanor M ^a   Stewart, V Ann ^b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b Uniformed Services University of the Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIRCUMSPOROZOITE PROTEIN; MALARIA VACCINE;

CELLULAR IMMUNITY; DRUG EFFICACY; INCIDENCE; INDIA; INFECTION RISK; MALARIA; MALARIA CONTROL; MALARIA FALCIPARUM; MORTALITY; PARASITE IMMUNITY; PASSIVE IMMUNIZATION; PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPIC PLASTICITY; PLASMODIUM KNOWLESI MALARIA; PLASMODIUM VIVAX MALARIA; PRIORITY JOURNAL; REVIEW; SOUTHEAST ASIA; VACCINATION;

ANIMALS; CLINICAL TRIALS AS TOPIC; GENETIC VARIATION; HUMANS; LIFE CYCLE STAGES; MALARIA; MALARIA VACCINES; PLASMODIUM; T-LYMPHOCYTES; VACCINATION;

EID: 84873564071     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3083     Document Type: Review

References (131)

1. World Health Organization. World malaria report 2011. World Health Organization. (2011
2. Murray, C.J. et al. Global malaria mortality between 1980 and 2010: A systematic analysis. Lancet 379, 413-431 (2012
3. Umbers, A.J., Aitken, E.H. & Rogerson, S.J. Malaria in pregnancy: Small babies, big problem. Trends Parasitol. 27, 168-175 (2011
4. Cox-Singh, J. et al. Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening. Clin. Infect. Dis. 46, 165-171 (2008 (Pubitemid 351269152)
5. O'Brien, C., Henrich, P.P., Passi, N. & Fidock, D.A. Recent clinical and molecular insights into emerging artemisinin resistance in Plasmodium falciparum. Curr. Opin. Infect. Dis. 24, 570-577 (2011
6. McNamara, C. & Winzeler, E.A. Target identification and validation of novel antimalarials. Future Microbiol. 6, 693-704 (2011
7. Ranson, H. et al. Pyrethroid resistance in African anopheline mosquitoes: What are the implications for malaria control? Trends Parasitol. 27, 91-98 (2011
8. Bousema, T. & Drakeley, C. Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination. Clin. Microbiol. Rev. 24, 377-410 (2011
9. Malaria Vaccine Technology Roadmap. Malaria vaccine technology roadmap. PATH Malaria Vaccine Initiative. (2006
10. Bill and Melinda Gates Foundation. Malaria strategy overview. Bill and Melinda Gates Foundation. (2011
11. Agnandji, S.T. et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N. Engl. J. Med. 365, 1863-1875 (2011
12. RTS,S Clinical Trials Partnership. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N. Engl. J. Med. 367, 2284-2295 (2012
13. Alonso, P.L. & Tanner, M. Public health challenges and prospects for malaria control and elimination. Nat. Med. 19, 150-155 (2013
14. Casares, S., Brumeanu, T.D. & Richie, T.L. The RTS,S malaria vaccine. Vaccine 28, 4880-4894 (2010
15. Garçon, N. & Van Mechelen, M. Recent clinical experience with vaccines using MPLand QS-21-containing adjuvant systems. Expert Rev. Vaccines 10, 471-486 (2011
16. Regules, J.A., Cummings, J.F. & Ockenhouse, C.F. The RTS,S vaccine candidate for malaria. Expert Rev. Vaccines 10, 589-599 (2011
17. Kester, K.E. et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: Safety, efficacy, and immunologic associates of protection. J. Infect. Dis. 200, 337-346 (2009
18. Stoute, J.A. et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N. Engl. J. Med. 336, 86-91 (1997 (Pubitemid 27020884)
19. Stoute, J.A. et al. Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine. J. Infect. Dis. 178, 1139-1144 (1998 (Pubitemid 28452210)
20. Olotu, A. et al. Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P falciparum clinical malaria. PLoS ONE 6, e25786 (2011
21. Ansong, D. et al. T cell responses to the RTS,S/AS01(E) and RTS,S/AS02(D) malaria candidate vaccines administered according to different schedules to Ghanaian children. PLoS ONE 6, e18891 (2011
22. Lumsden, J.M. et al. Protective immunity induced with the RTS,S/AS vaccine is associated with IL-2 and TNF-α producing effector and central memory CD4 T cells. PLoS ONE 6, e20775 (2011
23. Agnandji, S.T. et al. Induction of Plasmodium falciparum-specific CD4+ T cells and memory B cells in Gabonese children vaccinated with RTS,S/AS01(E) and RTS,S/ AS02(D). PLoS ONE 6, e18559 (2011
24. Horowitz, A. et al. Antigen-specific IL-2 secretion correlates with NK cell responses after immunization of Tanzanian children with the RTS,S/AS01 malaria vaccine. J. Immunol. 188, 5054-5062 (2012
25. Brice, G.T. et al. Extended immunization intervals enhance the immunogenicity and protective efficacy of plasmid DNA vaccines. Microbes Infect. 9, 1439-1446 (2007 (Pubitemid 350016978)
26. Elnekave, M., Bivas-Benita, M., Gillard, G.O., Sircar, P. & Hovav, A.H. A matter of timing: Unsynchronized antigen expression and antigen presentation diminish secondary T cell responses. J. Immunol. 183, 1013-1021 (2009
27. Abdulla, S. et al. Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. N. Engl. J. Med. 359, 2533-2544 (2008
28. Obar, J.J. & Lefrancois, L. Early signals during CD8 T cell priming regulate the generation of central memory cells. J. Immunol. 185, 263-272 (2010
29. Fousteri, G. et al. Increased memory conversion of naive CD8 T cells activated during late phases of acute virus infection due to decreased cumulative antigen exposure. PLoS ONE 6, e14502 (2011
30. Croom, H.A. et al. Memory precursor phenotype of CD8+ T cells reflects early antigenic experience rather than memory numbers in a model of localized acute influenza infection. Eur. J. Immunol. 41, 682-693 (2011
31. Alonso, P.L. et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: Single-blind extended follow-up of a randomised controlled trial. Lancet 366, 2012-2018 (2005 (Pubitemid 41773376)
32. Alonso, P.L. et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: Randomised controlled trial. Lancet 364, 1411-1420 (2004 (Pubitemid 39370716)
33. Bejon, P. et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N. Engl. J. Med. 359, 2521-2532 (2008
34. Sacarlal, J. et al. Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children. J. Infect. Dis. 200, 329-336 (2009
35. Aide, P. et al. Four year immunogenicity of the RTS,S/AS02(A) malaria vaccine in Mozambican children during a phase IIb trial. Vaccine 29, 6059-6067 (2011
36. Sutherland, C.J., Drakeley, C.J. & Schellenberg, D. How is childhood development of immunity to Plasmodium falciparum enhanced by certain antimalarial interventions? Malar. J. 6, 161 (2007
37. Takala, S.L. & Plowe, C.V. Genetic diversity and malaria vaccine design, testing and efficacy: Preventing and overcoming 'vaccine resistant malaria'. Parasite Immunol. 31, 560-573 (2009
38. Weedall, G.D. & Conway, D.J. Detecting signatures of balancing selection to identify targets of anti-parasite immunity. Trends Parasitol. 26, 363-369 (2010
39. Epstein, J.E., Giersing, B., Mullen, G., Moorthy, V. & Richie, T.L. Malaria vaccines: Are we getting closer? Curr. Opin. Mol. Ther. 9, 12-24 (2007 (Pubitemid 46438445)
40. Mackinnon, M.J. & Marsh, K. The selection landscape of malaria parasites. Science 328, 866-871 (2010
41. McKenzie, F.E., Smith, D.L., O'Meara, W.P. & Riley, E.M. Strain theory of malaria: The first 50 years. Adv. Parasitol. 66, 1-46 (2008 (Pubitemid 351672128)
42. Dzikowski, R. & Deitsch, K.W. Genetics of antigenic variation in Plasmodium falciparum. Curr. Genet. 55, 103-110 (2009
43. Pasternak, N.D. & Dzikowski, R. PfEMP1: An antigen that plays a key role in the pathogenicity and immune evasion of the malaria parasite Plasmodium falciparum. Int. J. Biochem. Cell Biol. 41, 1463-1466 (2009
44. Chen, D.S. et al. A molecular epidemiological study of var gene diversity to characterize the reservoir of Plasmodium falciparum in humans in Africa. PLoS ONE 6, e16629 (2011
45. Gupta, S., Snow, R.W., Donnelly, C.A., Marsh, K. & Newbold, C. Immunity to noncerebral severe malaria is acquired after one or two infections. Nat. Med. 5, 340-343 (1999 (Pubitemid 29124373)
46. Okell, L.C., Ghani, A.C., Lyons, E. & Drakeley, C.J. Submicroscopic infection in Plasmodium falciparum-endemic populations: A systematic review and meta-analysis. J. Infect. Dis. 200, 1509-1517 (2009
47. Riley E.M., Wahl, S., Perkins, D.J. & Schofield, L. Regulating immunity to malaria. Parasite Immunol. 28, 35-49 (2006
48. Finney, O.C., Riley, E.M. & Walther, M. Regulatory T cells in malaria - friend or foe? Trends Immunol. 31, 63-70 (2010
49. Hansen, D.S. & Schofield, L. Natural regulatory T cells in malaria: Host or parasite allies? PLoS Pathog. 6, e1000771 (2010
50. Sidjanski, S. & Vanderberg, J.P. Delayed migration of Plasmodium sporozoites from the mosquito bite site to the blood. Am. J. Trop. Med. Hyg. 57, 426-429 (1997 (Pubitemid 27439113)
51. Gilson, P.R. & Crabb, B.S. Morphology and kinetics of the three distinct phases of red blood cell invasion by Plasmodium falciparum merozoites. Int. J. Parasitol. 39, 91-96 (2009
52. Niederwieser, I., Felger, I. & Beck, H.P. Limited polymorphism in Plasmodium falciparum sexual-stage antigens. Am. J. Trop. Med. Hyg. 64, 9-11 (2001 (Pubitemid 32550090)
53. Liehl, P. & Mota, M.M. Innate recognition of malarial parasites by mammalian hosts. Int. J. Parasitol. 42, 557-566 (2012
54. Vanderberg, J.P., Khan, Z.M. & Stewart, M.J. Induction of hepatic inflammatory response by Plasmodium berghei sporozoites protects BALB/c mice against challenge with Plasmodium yoelii sporozoites. J. Parasitol. 79, 763-767 (1993 (Pubitemid 23333670)
55. Khan, Z.M. & Vanderberg, J.P. Specific inflammatory cell infiltration of hepatic schizonts in BALB/c mice immunized with attenuated Plasmodium yoelii sporozoites. Int. Immunol. 4, 711-718 (1992
56. Frevert, U. et al. Malaria circumsporozoite protein inhibits protein synthesis in mammalian cells. EMBO J. 17, 3816-3826 (1998 (Pubitemid 28333968)
57. Hügel, F.U., Pradel, G. & Frevert, U. Release of malaria circumsporozoite protein into the host cell cytoplasm and interaction with ribosomes. Mol. Biochem. Parasitol. 81, 151-170 (1996 (Pubitemid 26316557)
58. Bojang, K.A. et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: A randomised trial. Lancet 358, 1927-1934 (2001 (Pubitemid 34072872)
59. Polhemus, M.E. et al. Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area. PLoS ONE 4, e6465 (2009
60. Crispe, I.N. et al. Cellular and molecular mechanisms of liver tolerance. Immunol. Rev. 213, 101-118 (2006 (Pubitemid 44401496)
61. Dondorp, A.M. et al. Estimation of the total parasite biomass in acute falciparum malaria from plasma PfHRP2. PLoS Med. 2, e204 (2005
62. Cunnington, A.J., de Souza, J.B., Walther, M. & Riley, E.M. Malaria impairs resistance to Salmonella through heme- and heme oxygenase-dependent dysfunctional granulocyte mobilization. Nat. Med. 18, 120-127 (2012
63. Moormann, A.M., Snider, C.J. & Chelimo, K. The company malaria keeps: How coinfection with Epstein-Barr virus leads to endemic Burkitt lymphoma. Curr. Opin. Infect. Dis. 24, 435-441 (2011
64. Schwartz, L., Brown, G.V., Genton, B. & Moorthy, V.S. A review of malaria vaccine clinical projects based on the WHO rainbow table. Malar. J. 11, 11 (2012
65. The malERA Consultative Group on Vaccines. A research agenda for malaria eradication: Vaccines. PLoS Med. 8, e1000398 (2011
66. Doolan, D.L. Plasmodium immunomics. Int. J. Parasitol. 41, 3-20 (2011
67. Plowe, C.V., Alonso, P. & Hoffman, S.L. The potential role of vaccines in the elimination of falciparum malaria and the eventual eradication of malaria. J. Infect. Dis. 200, 1646-1649 (2009
68. Matuschewski, K., Hafalla, J.C., Borrmann, S. & Friesen, J. Arrested Plasmodium liver stages as experimental anti-malaria vaccines. Hum. Vaccin. (suppl. 7), 16-21 (2011
69. Cockburn, I.A. & Zavala, F. T cell memory in malaria. Curr. Opin. Immunol. 19, 424- 429 (2007 (Pubitemid 47284854)
70. Chakravarty, S. et al. CD8+ T lymphocytes protective against malaria liver stages are primed in skin-draining lymph nodes. Nat. Med. 13, 1035-1041 (2007 (Pubitemid 47517509)
71. Cockburn, I.A. et al. Dendritic cells and hepatocytes use distinct pathways to process protective antigen from Plasmodium in vivo. PLoS Pathog. 7, e1001318 (2011
72. Matuschewski, K., Hafalla, J.C., Borrmann, S. & Friesen, J. Arrested Plasmodium liver stages as experimental anti-malaria vaccines. Hum. Vaccin. (suppl. 7), 16-21 (2011
73. Weiss, W.R. & Jiang, C.G. Protective CD8+ T lymphocytes in primates immunized with malaria sporozoites. PLoS ONE 7, e31247 (2012
74. Lindner, S.E., Miller, J.L. & Kappe, S.H. Malaria parasite pre-erythrocytic infection: Preparation meets opportunity. Cell. Microbiol. 14, 316-324 (2012
75. Hoffman, S.L. et al. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum. Vaccin. 6, 97-106 (2010
76. Vaughan, A.M., Wang, R. & Kappe, S.H. Genetically engineered, attenuated whole-cell vaccine approaches for malaria. Hum. Vaccin. 6, 107-113 (2010
77. Epstein, J.E. et al. Live attenuated malaria vaccine designed to protect through hepatic CD8 T cell immunity. Science 334, 475-480 (2011
78. Lee, S.W. et al. Attenuated vaccines can recombine to form virulent field viruses. Science 337, 188 (2012
79. Genton, B. et al. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J. Infect. Dis. 185, 820-827 (2002 (Pubitemid 34226210)
80. Thera, M.A. et al. A field trial to assess a blood-stage malaria vaccine. N. Engl. J. Med. 365, 1004-1013 (2011
81. Engwerda, C.R., Beattie, L. & Amante, F.H. The importance of the spleen in malaria. Trends Parasitol. 21, 75-80 (2005 (Pubitemid 40138879)
82. Douglas, A.D. et al. The blood-stage malaria antigen PfRH5 is susceptible to vaccineinducible cross-strain neutralizing antibody. Nat. Commun. 2, 601 (2011
83. Crosnier, C. et al. Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum. Nature 480, 534-537 (2011
84. Tham, W.H., Healer, J. & Cowman, A.F. Erythrocyte and reticulocyte binding-like proteins of Plasmodium falciparum. Trends Parasitol. 28, 23-30 (2012
85. Cohen, S., Mc, G.I. & Carrington, S. γ-globulin and acquired immunity to human malaria. Nature 192, 733-737 (1961
86. Sabchareon, A. et al. Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am. J. Trop. Med. Hyg. 45, 297-308 (1991
87. Fowkes, F.J., Richards, J.S., Simpson, J.A. & Beeson, J.G. The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis. PLoS Med. 7, e1000218 (2010
88. Riley, E.M., Jepsen, S., Andersson, G., Otoo, L.N. & Greenwood, B.M. Cell-mediated immune responses to Plasmodium falciparum antigens in adult Gambians. Clin. Exp. Immunol. 71, 377-382 (1988 (Pubitemid 18079369)
89. Troye-Blomberg, M. et al. Production by activated human T cells of interleukin 4 but not interferon-γ is associated with elevated levels of serum antibodies to activating malaria antigens. Proc. Natl. Acad. Sci. USA 87, 5484-5488 (1990
90. Teirlinck, A.C. et al. Longevity and composition of cellular immune responses following experimental Plasmodium falciparum malaria infection in humans. PLoS Pathog. 7, e1002389 (2011
91. Huaman, M.C. et al. Ex vivo cytokine and memory T cell responses to the 42-kDa fragment of Plasmodium falciparum merozoite surface protein-1 in vaccinated volunteers. J. Immunol. 180, 1451-1461 (2008
92. Stevenson, M.M. & Riley, E.M. Innate immunity to malaria. Nat. Rev. Immunol. 4, 169-180 (2004
93. Langhorne, J., Ndungu, F.M., Sponaas, A.M. & Marsh, K. Immunity to malaria: More questions than answers. Nat. Immunol. 9, 725-732 (2008 (Pubitemid 351859155)
94. Pombo, D.J. et al. Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet 360, 610-617 (2002 (Pubitemid 35232195)
95. Roestenberg, M. et al. Protection against a malaria challenge by sporozoite inoculation. N. Engl. J. Med. 361, 468-477 (2009
96. Roestenberg, M. et al. Long-term protection against malaria after experimental sporozoite inoculation: An open-label follow-up study. Lancet 377, 1770-1776 (2011
97. Butler, N.S. et al. Superior antimalarial immunity after vaccination with late liver stagearresting genetically attenuated parasites. Cell Host Microbe 9, 451-462 (2011
98. Friesen, J. et al. Natural immunization against malaria: Causal prophylaxis with antibiotics. Sci. Transl. Med. 2, 40ra49 (2010
99. Hviid, L. The role of Plasmodium falciparum variant surface antigens in protective immunity and vaccine development. Hum. Vaccin. 6, 84-89 (2010
100. Janes, J.H. et al. Investigating the host binding signature on the Plasmodium falciparum PfEMP1 protein family. PLoS Pathog. 7, e1002032 (2011
101. Saul, A. Mosquito stage, transmission blocking vaccines for malaria. Curr. Opin. Infect. Dis. 20, 476-481 (2007 (Pubitemid 47359643)
102. van der Kolk, M. et al. Evaluation of the standard membrane feeding assay (SMFA) for the determination of malaria transmission-reducing activity using empirical data. Parasitology 130, 13-22 (2005
103. Todryk, S.M. et al. Multiple functions of human T cells generated by experimental malaria challenge. Eur. J. Immunol. 39, 3042-3051 (2009
104. Reyes-Sandoval, A. et al. CD8+ T effector memory cells protect against liver-stage malaria. J. Immunol. 187, 1347-1357 (2011
105. Tamminga, C. et al. Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: Safety, immunogenicity and protective efficacy of the CSP component. PLoS ONE 6, e25868 (2011
106. Forbes, E.K. et al. Combining liver- and blood-stage malaria viral-vectored vaccines: Investigating mechanisms of CD8+ T cell interference. J. Immunol. 187, 3738-3750 (2011
107. Reyes-Sandoval, A. et al. Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. Infect. Immun. 78, 145-153 (2010
108. Stewart, V.A. et al. Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone. Infect. Immun. 75, 2283-2290 (2007 (Pubitemid 46744316)
109. Vuola, J.M. et al. Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers. J. Immunol. 174, 449-455 (2005 (Pubitemid 40007434)
110. Bejon, P. et al. Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area. Vaccine 24, 4709-4715 (2006 (Pubitemid 43776788)
111. Nie, C.Q. et al. IP-10-mediated T cell homing promotes cerebral inflammation over splenic immunity to malaria infection. PLoS Pathog. 5, e1000369 (2009
112. Van den Steen, P.E. et al. CXCR3 determines strain susceptibility to murine cerebral malaria by mediating T lymphocyte migration toward IFN-γ-induced chemokines. Eur. J. Immunol. 38, 1082-1095 (2008
113. Berthoud, T.K., Dunachie, S.J., Todryk, S., Hill, A.V. & Fletcher, H.A. MIG (CXCL9) is a more sensitive measure than IFN-γ of vaccine induced T-cell responses in volunteers receiving investigated malaria vaccines. J. Immunol. Methods 340, 33-41 (2009
114. Querec, T.D. et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat. Immunol. 10, 116-125 (2009
115. Nakaya, H.I. et al. Systems biology of vaccination for seasonal influenza in humans. Nat. Immunol. 12, 786-795 (2011
116. Andersen-Nissen, E., Heit, A. & McElrath, M.J. Profiling immunity to HIV vaccines with systems biology. Curr. Opin. HIV AIDS 7, 32-37 (2012
117. Luke, T.C. & Hoffman, S.L. Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine. J. Exp. Biol. 206, 3803-3808 (2003 (Pubitemid 37365462)
118. Uthaipibull, C. et al. Inhibitory and blocking monoclonal antibody epitopes on merozoite surface protein 1 of the malaria parasite Plasmodium falciparum. J. Mol. Biol. 307, 1381-1394 (2001 (Pubitemid 33027647)
119. Nwuba, R.I. et al. The human immune response to Plasmodium falciparum includes both antibodies that inhibit merozoite surface protein 1 secondary processing and blocking antibodies. Infect. Immun. 70, 5328-5331 (2002
120. Voss, T.S. et al. A var gene promoter controls allelic exclusion of virulence genes in Plasmodium falciparum malaria. Nature 439, 1004-1008 (2006 (Pubitemid 43292421)
121. O'Donnell, R.A., Saul, A., Cowman, A.F. & Crabb, B.S. Functional conservation of the malaria vaccine antigen MSP-119 across distantly related Plasmodium species. Nat. Med. 6, 91-95 (2000 (Pubitemid 30048533)
122. Doolan, D.L., Dobano, C. & Baird, J.K. Acquired immunity to malaria. Clin. Microbiol. Rev. 22, 13-36 (2009
123. Weiss, G.E. et al. Atypical memory B cells are greatly expanded in individuals living in a malaria-endemic area. J. Immunol. 183, 2176-2182 (2009
124. Bodescot, M. et al. Transcription status of vaccine candidate genes of Plasmodium falciparum during the hepatic phase of its life cycle. Parasitol. Res. 92, 449-452 (2004 (Pubitemid 38658337)
125. Epstein, J.E. et al. Safety and clinical outcome of experimental challenge of human volunteers with Plasmodium falciparum-infected mosquitoes: An update. J. Infect. Dis. 196, 145-154 (2007 (Pubitemid 46982749)
126. Bousema, T. et al. Revisiting the circulation time of Plasmodium falciparum gametocytes: Molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs. Malar. J. 9, 136 (2010
127. Bousema, T. et al. The dynamics of naturally acquired immune responses to Plasmodium falciparum sexual stage antigens Pfs230 & Pfs48/45 in a low endemic area in Tanzania. PLoS ONE 5, e14114 (2010
128. Bojang, K.A. RTS,S/AS02A for malaria. Expert Rev. Vaccines 5, 611-615 (2006 (Pubitemid 46021043)
129. Nussenzweig, V. & Nussenzweig, R.S. Rationale for the development of an engineered sporozoite malaria vaccine. Adv. Immunol. 45, 283-334 (1989 (Pubitemid 19195509)
130. Heppner, D.G. & Ballou, W.R. Malaria in 1998: Advances in diagnosis, drugs and vaccine development. Curr. Opin. Infect. Dis. 11, 519-530 (1998 (Pubitemid 28510493)
131. Ballou, W.R. The development of the RTS,S malaria vaccine candidate: Challenges and lessons. Parasite Immunol. 31, 492-500 (2009